Article Type
Changed
Wed, 06/01/2022 - 12:59

Key clinical point: A new breath biomarker-based diagnostic method shows promise by identifying 16 cancer-derived volatile organic compounds (VOC) that have high sensitivity and specificity in patients with lung cancer.

 

Major finding: In the discovery phase, 16 VOC with peak intensity most altered before vs after surgery were identified. In the validation phase, the 16 VOC-based diagnostic model demonstrated an area under the curve of 0.952, sensitivity of 89.2%, specificity of 89.1%, and accuracy of 89.1%.

 

Study details: The discovery phase involved a prospective cohort study of 84 patients with lung cancer who were tested for 28 VOC before and after surgery. The promising VOC were further assessed in the validation phase which included 157 patients with lung cancer and 368 healthy controls.

 

Disclosures: The research was funded by the National Natural Science Foundation of China and others. The authors declared no competing interests.

 

Source: Wang P et al. Identification of lung cancer breath biomarkers based on perioperative breathomics testing: A prospective observational study. EClinicalMedicine. 2022;47:101384 (Apr 26). Doi: 10.1016/j.eclinm.2022.101384

Publications
Topics
Sections

Key clinical point: A new breath biomarker-based diagnostic method shows promise by identifying 16 cancer-derived volatile organic compounds (VOC) that have high sensitivity and specificity in patients with lung cancer.

 

Major finding: In the discovery phase, 16 VOC with peak intensity most altered before vs after surgery were identified. In the validation phase, the 16 VOC-based diagnostic model demonstrated an area under the curve of 0.952, sensitivity of 89.2%, specificity of 89.1%, and accuracy of 89.1%.

 

Study details: The discovery phase involved a prospective cohort study of 84 patients with lung cancer who were tested for 28 VOC before and after surgery. The promising VOC were further assessed in the validation phase which included 157 patients with lung cancer and 368 healthy controls.

 

Disclosures: The research was funded by the National Natural Science Foundation of China and others. The authors declared no competing interests.

 

Source: Wang P et al. Identification of lung cancer breath biomarkers based on perioperative breathomics testing: A prospective observational study. EClinicalMedicine. 2022;47:101384 (Apr 26). Doi: 10.1016/j.eclinm.2022.101384

Key clinical point: A new breath biomarker-based diagnostic method shows promise by identifying 16 cancer-derived volatile organic compounds (VOC) that have high sensitivity and specificity in patients with lung cancer.

 

Major finding: In the discovery phase, 16 VOC with peak intensity most altered before vs after surgery were identified. In the validation phase, the 16 VOC-based diagnostic model demonstrated an area under the curve of 0.952, sensitivity of 89.2%, specificity of 89.1%, and accuracy of 89.1%.

 

Study details: The discovery phase involved a prospective cohort study of 84 patients with lung cancer who were tested for 28 VOC before and after surgery. The promising VOC were further assessed in the validation phase which included 157 patients with lung cancer and 368 healthy controls.

 

Disclosures: The research was funded by the National Natural Science Foundation of China and others. The authors declared no competing interests.

 

Source: Wang P et al. Identification of lung cancer breath biomarkers based on perioperative breathomics testing: A prospective observational study. EClinicalMedicine. 2022;47:101384 (Apr 26). Doi: 10.1016/j.eclinm.2022.101384

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Lung Cancer June 2022
Gate On Date
Tue, 05/24/2022 - 16:30
Un-Gate On Date
Tue, 05/24/2022 - 16:30
Use ProPublica
CFC Schedule Remove Status
Tue, 05/24/2022 - 16:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article